Usküdar Teke Hava, Akay Olga Meltem, Gören Şahin Deniz, Karagülle Mustafa, Gündüz Eren, Andıç Neslihan
Hematology, Medical Faculty, Eskişehir Osmangazi University, 26090 Eskişehir, Turkey.
Case Rep Med. 2014;2014:203939. doi: 10.1155/2014/203939. Epub 2014 Sep 9.
Pleural effusion, as a side effect of tyrosine kinases, may be seen as most commonly associated with dasatinib and very rarely seen with nilotinib. In this report we present a chronic phase of CML case that was treated with nilotinib due to imatinib (Gleevec) allergy and had pleural effusion with nilotinib at 5th year of treatment. If pleural effusion develops in patients taking nilotinib and if this effusion is exudative and lymphocyte predominant, after ruling out pulmonary and cardiac etiologies, it must be associated with nilotinib; according to stage of effusion drug should be discontinued and/or steroid should be started and/or surgery should be performed.
胸腔积液作为酪氨酸激酶的一种副作用，最常与达沙替尼相关，而与尼罗替尼的相关性则极为罕见。在本报告中，我们呈现了1例慢性期慢性粒细胞白血病患者，该患者因对伊马替尼（格列卫）过敏而接受尼罗替尼治疗，在治疗的第5年出现了与尼罗替尼相关的胸腔积液。如果服用尼罗替尼的患者出现胸腔积液，且该积液为渗出液且以淋巴细胞为主，在排除肺部和心脏病因后，必定与尼罗替尼有关；应根据积液的阶段停用药物和/或开始使用类固醇和/或进行手术。
